Dupixent dupilumab can be purchased in hospitals, but it requires an application. The price is unknown and may be partially reimbursed by the state.
The world’s first and only targeted biological agent Dalbitux (duplimumab injection) approved for the treatment of moderate to severe atopic dermatitis in adults was developed by Professor Zhang Jianzhong, Director of the Department of Dermatology, Peking University People’s Hospital The first prescription in Beijing was issued.
On the same day, at the outpatient clinic of Professor Xu Jinhua, Director of the Dermatology Department of Huashan Hospital Affiliated to Fudan University, and the outpatient clinic of Professor Yang Bin, Chief Physician of the Dermatology Hospital of Southern Medical University, patients in both places also received this new drug.
Benefiting from the promotion of the national drug regulatory reform, Dalbital was approved two years earlier than originally planned; benefiting from the accelerated import inspection process of innovative drugs, Dalbital was approved from June 28 The Imported Drug Registration Certificate (IDL) will be officially available nationwide on July 22, setting a new record for the speed of biologics being launched in China in just 25 days.
According to reports, moderate to severe atopic dermatitis (AD) is a refractory, relapsing, inflammatory skin disease, with recurring severe itching and rash as the main clinical manifestations. Patients often suffer from allergic rhinitis, asthma and other atopic diseases. Multiple surveys in Asian countries and regions have shown that the prevalence of atopic dermatitis in adults is 0.9%-2.1%.